Facebook removes 1.5 million horrific videos of New Zealand terror attack

Washington, Jun 2: There is no place for hate and racism in the society, Microsoft CEO Satya Nadella has said, asserting that empathy and shared understanding are a start, but more needs to be done. Nadella’s remarks come in the wake of the custodial death of George Floyd, a 46-year-old African-American man who was pinned to the ground in Minneapolis on May 25 by a white police officer who kneeled on his neck as he gasped for breath.

“There is no place for hate and racism in our society. Empathy and shared understanding are a start, but we must do more,” Nadella said in a tweet on Monday.

“I stand with the Black and African American community and we are committed to building on this work in our company and in our communities,” Nadella said.

A day earlier, Google CEO Sunder Pichai expressed solidarity with the African-American community.

“Today on US Google & YouTube homepages we share our support for racial equality in solidarity with the Black community and in memory of George Floyd, Breonna Taylor, Ahmaud Arbery & others who don’t have a voice,” Pichai wrote on Twitter on Sunday.

“For those feeling grief, anger, sadness & fear, you are not alone,” Pichai said, sharing a screenshot of the Google search home page which said, “We stand in support of racial equality, and all those who search for it.”

Nadella’s Microsoft also said they will be using the platform to amplify voices from the Black and African American community at the company.

Nadella had also spoken out a few months ago about the discriminatory Citizenship Amendment Act passed in his native country. Talking to BuzzFeed’s editor-in-chief, Ben Smith, in Manhattan, Nadella said what’s happening in the country is “sad.”

“I think what is happening is sad. I feel, and in fact quite frankly, now being informed (and) shaped by the two amazing American things that I’ve observed which is both, it’s technology reaching me where I was growing up and its immigration policy and even a story like mine being possible in a country like this.

“I think, it’s just bad, if anything, I would love to see a Bangladeshi immigrant who comes to India and creates the next unicorn in India or becomes the CEO of Infosys. That should be the aspiration. If I had to sort of mirror what happened to me in the US, I hope that’s what happens in India,” Microsoft’s India-born CEO was quoted as saying by BuzzFeed.

Hubei, Feb 10: The death toll in the deadly coronavirus outbreak in China and other parts of the world has reached 904, CNN reported citing Chinese authorities on Monday.

The number of infected people globally has now hit the 40,000 mark.

According to the country's health officials, the number of people, who died from coronavirus in the Hubei Province, has risen to 871.

"As of 24:00 on February 9, Hubei Province reported a total of 29,631 cases of new coronavirus pneumonia, including 16,902 cases in Wuhan. 22,160 patients are still being treated in hospitals. 73,127 people remain under medical observation," read the statement from the Chinese Regional Health Committee.

The novel coronavirus was first detected in China's Wuhan city in late December and has since spread to more than 25 countries.

On Sunday, the new coronavirus even surpassed the fatalities caused by the SARS epidemic in 2003.

The World Health Organisation (WHO) has declared a global health emergency in the wake of the outbreak.

Meanwhile, WHO's international expert mission led by Dr Bruce Aylward embarked for China.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.